SummitUS86627T1088SMMTSMMT
There is no discussion about the security yet. Share your thoughts now!
Financials
Market Cap
$17.79B5Y beta
-1.08EPS (TTM)
-$0.23Free Float
102.39MEBITDA (TTM)
-$143.59MFree Cashflow (TTM)
-$97.61MPricing
Analyst Ratings
The price target is $13.50 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.